NO_LONGER_AVAILABLENCT04374370
SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)
Studying Severe acute respiratory syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AdventHealth
- Principal Investigator
- Eduardo Oliveira, MDAdventHealth
- Intervention
- SARSCoV2 Convalescent Plasma(biological)
- Eligibility
- 6-99 years · All sexes
Study locations (1)
- AdventHealth Orlando, Orlando, Florida, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04374370 on ClinicalTrials.govOther trials for Severe acute respiratory syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06099795Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2Centre Hospitalier Universitaire de Nīmes
- RECRUITINGPHASE4NCT06585241A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsModernaTX, Inc.
- RECRUITINGNCT06168019Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in IndiaBoston University
- RECRUITINGEARLY PHASE1NCT05656105Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) InfectionUniversity of Alabama at Birmingham
- RECRUITINGNCT05892549COVID-19: Early Detection of Worsening by Voice and Respiratory Pattern CharacteristicsDirection Centrale du Service de Santé des Armées
- RECRUITINGNANCT05566483Physiology of Long COVID-19 and the Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional CapacityUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGNCT05787964Immunity to Infection in Healthy Participants and Participants With CancerUniversity Hospital Tuebingen
- RECRUITINGPHASE2, PHASE3NCT05543616A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy ChildrenBioNTech SE